According to Regencell Bioscience's latest financial reports the company has a price-to-book ratio of 7.04.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2023-12-31 | 11.4 | -53.92% |
2022-12-31 | 24.7 | 17.97% |
2021-12-31 | 21.0 | |
2020-12-31 | N/A |